Two Decades of Advances in Colorectal Cancer Prevention and Treatment: From Aspirin to Precision Oncology

Dear Colleagues,

This Special Issue, ‘Two Decades of Advances in Colorectal Cancer Prevention and Treatment: From Aspirin to Precision Oncology’, highlights the remarkable progress made in colorectal cancer research, prevention, and clinical management over the last twenty years. As our understanding of the disease has deepened, innovative approaches, from chemoprevention strategies to precision-guided therapies, have transformed patient care and outcomes.

This Special Issue seeks to present a curated collection of original research, comprehensive reviews, and expert insights that explore the evolution of colorectal cancer treatment, the integration of precision medicine, and the development of novel strategies to address ongoing clinical challenges.

The scope of the Special Issue includes, but is not limited to, the following:

• Molecular mechanisms of colorectal carcinogenesis: Insights into key signaling pathways and genetic alterations driving disease progression.
• Chemoprevention: Efficacy and mechanisms of agents such as aspirin, NSAIDs, and dietary compounds in reducing colorectal cancer risk.
• Innovations in screening and early detection: Advances in molecular diagnostics, imaging modalities, and non-invasive tools, including liquid biopsy (e.g., ctDNA, microRNAs).
• Targeted therapies: Development and clinical application of EGFR inhibitors, VEGF inhibitors, BRAF inhibitors, and rational combination therapies.
• Immunotherapy approaches: Progress in checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and the immunogenomic landscape of colorectal tumors.
• Precision oncology: Application of genomic, transcriptomic, epigenomic, and proteomic data to tailor treatment strategies to individual patients.
• Emerging therapeutics: Investigating novel drug targets, biomarker-driven combination regimens, and adaptive treatment approaches.
• Therapy resistance: Understanding and overcoming resistance to chemotherapy, targeted therapies, and immunotherapies.

We invite contributions that capture the significant strides made in colorectal cancer care and explore future opportunities for innovation in precision oncology.

Dr. Manish Tripathi
Dr. Puneet Vij
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• immunotherapy
• biomarkers
• colorectal cancer
• targeted therapies
• molecular pathways